Owkin France, Paris, France.
Medipath, Fréjus, France.
Nat Commun. 2023 Nov 6;14(1):6695. doi: 10.1038/s41467-023-42453-6.
Mismatch Repair Deficiency (dMMR)/Microsatellite Instability (MSI) is a key biomarker in colorectal cancer (CRC). Universal screening of CRC patients for MSI status is now recommended, but contributes to increased workload for pathologists and delayed therapeutic decisions. Deep learning has the potential to ease dMMR/MSI testing and accelerate oncologist decision making in clinical practice, yet no comprehensive validation of a clinically approved tool has been conducted. We developed MSIntuit, a clinically approved artificial intelligence (AI) based pre-screening tool for MSI detection from haematoxylin-eosin (H&E) stained slides. After training on samples from The Cancer Genome Atlas (TCGA), a blind validation is performed on an independent dataset of 600 consecutive CRC patients. Inter-scanner reliability is studied by digitising each slide using two different scanners. MSIntuit yields a sensitivity of 0.96-0.98, a specificity of 0.47-0.46, and an excellent inter-scanner agreement (Cohen's κ: 0.82). By reaching high sensitivity comparable to gold standard methods while ruling out almost half of the non-MSI population, we show that MSIntuit can effectively serve as a pre-screening tool to alleviate MSI testing burden in clinical practice.
错配修复缺陷(dMMR)/微卫星不稳定(MSI)是结直肠癌(CRC)的一个关键生物标志物。现在推荐对 CRC 患者进行 MSI 状态的普遍筛查,但这增加了病理学家的工作量,并延迟了治疗决策。深度学习有可能简化 dMMR/MSI 检测,并加速临床实践中肿瘤学家的决策,但尚未对经过临床批准的工具进行全面验证。我们开发了 MSIntuit,这是一种经过临床批准的人工智能(AI)基于血液学染色幻灯片的 MSI 检测的预筛选工具。在对来自癌症基因组图谱(TCGA)的样本进行训练后,我们在 600 例连续 CRC 患者的独立数据集上进行了盲法验证。通过使用两种不同的扫描仪对每张幻灯片进行数字化处理来研究扫描仪间的可靠性。MSIntuit 的灵敏度为 0.96-0.98,特异性为 0.47-0.46,并且具有出色的扫描仪间一致性(Cohen's κ:0.82)。通过达到与金标准方法相当的高灵敏度,同时排除了近一半的非 MSI 人群,我们表明 MSIntuit 可以有效地作为一种预筛选工具,以减轻临床实践中的 MSI 检测负担。